Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. Cancer J Clin. 2019;69:7–34. https://doi.org/10.3322/caac.21551.

Article  Google Scholar 

Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:s6243–9. https://doi.org/10.1158/1078-0432.ccr-06-0931.

Article  Google Scholar 

Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–6. https://doi.org/10.1038/bjc.1987.13.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132:931–9. https://doi.org/10.1043/1543-2165(2008)132[931:mpocrf]2.0.co;2.

Article  PubMed  Google Scholar 

Lee YT. Breast carcinoma: pattern of metastasis at autopsy. J Surg Oncol. 1983;23:175–80. https://doi.org/10.1002/jso.2930230311.

Article  CAS  PubMed  Google Scholar 

Contractor KB, Kenny LM, Stebbing J, Rosso L, Ahmad R, Jacob J, et al. [18F]-3’Deoxy-3’-fluorothymidine positron emission tomography and breast cancer response to docetaxel. Clin Cancer Res. 2011;17:7664–72. https://doi.org/10.1158/1078-0432.ccr-11-0783.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

World Health O. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization; 1979.

Google Scholar 

Riedl CC, Pinker K, Ulaner GA, Ong LT, Baltzer P, Jochelson MS, et al. Comparison of FDG-PET/CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017;44:1428–37. https://doi.org/10.1007/s00259-017-3703-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cook GJR, Goh V. Molecular imaging of bone metastases and their response to Therapy. J Nucl Med. 2020;61:799–806. https://doi.org/10.2967/jnumed.119.234260.

Article  CAS  PubMed  Google Scholar 

Cook GJ, Azad GK, Goh V. Imaging bone metastases in breast Cancer: Staging and Response Assessment. J Nucl Med. 2016;57(Suppl 1):s27–33. https://doi.org/10.2967/jnumed.115.157867.

Article  CAS  Google Scholar 

Costelloe CM, Chuang HH, Madewell JE, Ueno NT. Cancer Response Criteria and Bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer. 2010;1:80–92. https://doi.org/10.7150/jca.1.80.

Article  PubMed  PubMed Central  Google Scholar 

Gallamini A, Zwarthoed C, Borra A. Positron Emission Tomography (PET) in Oncology. Cancers. 2014;6:1821–89. https://doi.org/10.3390/cancers6041821.

Article  PubMed  PubMed Central  Google Scholar 

Weber WA. Assessing tumor response to therapy. J Nucl Med. 2009;50(Suppl 1):S1–10. https://doi.org/10.2967/jnumed.108.057174.

Article  CAS  Google Scholar 

Coudert B, Pierga JY, Mouret-Reynier MA, Kerrou K, Ferrero JM, Petit T, et al. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. Lancet Oncol. 2014;15:1493–502. https://doi.org/10.1016/s1470-2045(14)70475-9.

Article  CAS  PubMed  Google Scholar 

Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, et al. TBCRC 008: early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015;56:31–7. https://doi.org/10.2967/jnumed.114.144741.

Article  PubMed  Google Scholar 

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, et al. TBCRC026: phase II trial correlating standardized uptake value with pathologic complete response to Pertuzumab and Trastuzumab in breast Cancer. J Clin Oncol. 2019;37:714–22. https://doi.org/10.1200/jco.2018.78.7986.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dunnwald LK, Doot RK, Specht JM, Gralow JR, Ellis GK, Livingston RB, et al. PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res. 2011;17:2400–9. https://doi.org/10.1158/1078-0432.ccr-10-2649.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, et al. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med. 2013;54:1862–8. https://doi.org/10.2967/jnumed.112.119271.

Article  CAS  PubMed  Google Scholar 

Groheux D, Cochet A, Humbert O, Alberini JL, Hindié E, Mankoff D. 18F-FDG PET/CT for staging and restaging of breast Cancer. J Nucl Med. 2016;57(Suppl 1):s17–26. https://doi.org/10.2967/jnumed.115.157859.

Article  CAS  Google Scholar 

Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, et al. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer. Eur J Nucl Med Mol Imaging. 2018;45:1279–88. https://doi.org/10.1007/s00259-018-3998-z.

Article  CAS  PubMed  Google Scholar 

Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A, et al. Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Annals Oncology: Official J Eur Soc Med Oncol. 2012;23:2572–7. https://doi.org/10.1093/annonc/mds071.

Article  CAS  Google Scholar 

Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3’-deoxy-3’-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339–47. https://doi.org/10.1007/s00259-007-0379-4.

Article  PubMed  Google Scholar 

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, et al. A phase II study of 3’-Deoxy-3’-18F-Fluorothymidine PET in the Assessment of early response of breast Cancer to Neoadjuvant Chemotherapy: results from ACRIN 6688. J Nucl Med. 2015;56:1681–9. https://doi.org/10.2967/jnumed.115.160663.

Article  CAS  PubMed  Google Scholar 

Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, et al. Phase II study of Lapatinib in Combination with Trastuzumab in patients with human epidermal growth factor receptor 2-Positive metastatic breast Cancer: clinical outcomes and predictive value of early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015;33:2623–31. https://doi.org/10.1200/jco.2014.60.0353.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, et al. Updated results of TBCRC026: phase II trial correlating standardized uptake value with pathological complete response to Pertuzumab and Trastuzumab in breast Cancer. J Clin Oncol. 2021;39:2247–56. https://doi.org/10.1200/jco.21.00280.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773–82. https://doi.org/10.1016/s0959-8049(99)00229-4.

Article  CAS  PubMed  Google Scholar 

Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):S122–50. https://doi.org/10.2967/jnumed.108.057307.

Article  CAS  Google Scholar 

Pinker K, Riedl C, Weber WA. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments. Eur J Nucl Med Mol Imaging. 2017;44:55–66. https://doi.org/10.1007/s00259-017-3687-3.

Article  PubMed  PubMed Central  Google Scholar 

Pinker K. Advanced Imaging for Precision Medicine in breast Cancer: from morphology to function. Breast care (Basel Switzerland). 2017;12:208–10. https://doi.org/10.1159/000480397.

Article  PubMed  Google Scholar 

Tateishi U, Gamez C, Dawood S, Yeung HW, Cristofanilli M, Macapinlac HA. Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. Radiology. 2008;247:189–96. https://doi.org/10.1148/radiol.2471070567.

Article  PubMed  Google Scholar 

Peterson LM, O’Sullivan J, Wu QV, Novakova-Jiresova A, Jenkins I, Lee JH, et al. Prospective study of serial (18)F-FDG PET and (18)F-Fluoride PET to predict time to skeletal-related events, Time to Progression, and Survival in patients with Bone-Dominant metastatic breast Cancer. J Nucl Med. 2018;59:1823–30. https://doi.org/10.2967/jnumed.118.211102.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinahan PE, Perlman ES, Sunderland JJ, Subramaniam R, Wollenweber SD, Turkington TG, et al. The QIBA Profile for FDG PET/CT as an imaging biomarker measuring response to Cancer Therapy. Radiology. 2020;294:647–57. https://doi.org/10.1148/radiol.2019191882.

Article